(Q46242920)

English

Rationale for fixed dosing of pertuzumab in cancer patients based on population pharmacokinetic analysis

scientific article published on 26 May 2006

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/16715358

Rationale for fixed dosing of pertuzumab in cancer patients based on population pharmacokinetic analysis (English)

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/16715358

pharmacokinetics

1 reference

based on heuristic

inferred from title

author name string

Chee M Ng

1

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/16715358

Bert L Lum

2

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/16715358

Veronica Gimenez

3

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/16715358

Steve Kelsey

4

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/16715358

David Allison

5

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/16715358

publication date

26 May 2006

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/16715358

Pharmaceutical Research

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/16715358

23

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/16715358

6

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/16715358

1275-1284

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/16715358

Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001.

1 reference

https://api.crossref.org/works/10.1007%2FS11095-006-0205-X

21 January 2018

Pharmacokinetics, Safety, and Efficacy of Trastuzumab Administered Every Three Weeks in Combination With Paclitaxel

1 reference

https://pubmed.ncbi.nlm.nih.gov/16715358

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

ErbB-targeted therapeutic approaches in human cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/16715358

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Impact of body-size measures on irinotecan clearance: alternative dosing recommendations

1 reference

https://pubmed.ncbi.nlm.nih.gov/16715358

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab

1 reference

https://pubmed.ncbi.nlm.nih.gov/16715358

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Flat-fixed dosing of irinotecan: influence on pharmacokinetic and pharmacodynamic variability

1 reference

https://pubmed.ncbi.nlm.nih.gov/16715358

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Assessment of actual significance levels for covariate effects in NONMEM.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16715358

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Molecular mechanisms underlying ErbB2/HER2 action in breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/16715358

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dosing strategies for anticancer drugs: the good, the bad and body-surface area

1 reference

https://pubmed.ncbi.nlm.nih.gov/16715358

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Untangling the ErbB signalling network

1 reference

https://pubmed.ncbi.nlm.nih.gov/16715358

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/16715358

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure

1 reference

https://pubmed.ncbi.nlm.nih.gov/16715358

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check

1 reference

https://pubmed.ncbi.nlm.nih.gov/16715358

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth

1 reference

https://pubmed.ncbi.nlm.nih.gov/16715358

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Horseshoes, hand grenades, and body-surface area-based dosing: aiming for a target

1 reference

https://pubmed.ncbi.nlm.nih.gov/16715358

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ready to partner

1 reference

https://pubmed.ncbi.nlm.nih.gov/16715358

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inter- and intrapatient variability in oral topotecan pharmacokinetics: implications for body-surface area dosage regimens.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16715358

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S11095-006-0205-X

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/16715358

1 reference

Europe PubMed Central

20 December 2017

http://europepmc.org/abstract/MED/16715358

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46242920&oldid=2143298914"